Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U02 Substudy 02C: Pembrolizumab-Based Neoadjuvant Therapy in Stage III Melanoma
2023-506314-51-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma (7 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants who experience an adverse event, Percentage of participants who discontinue study treatment due to an adverse event and 1 more. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-506314-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506314-51-00.